Mylan Partner Mabion Withdraws Rituximab In EU
US Firm Had Been Hopeful Of Launch This Year
Mabion’s European applications for biosimilar rituximab have been withdrawn, shortly after partner Mylan indicated it was hopeful of potential market entry this year, with a change of strategy necessitating a new application be filed with the EMA.
